Abstract:Afatinib, an irreversible ErbB family blocker, inhibits signalling from all homo- and hetero-dimers of ErbB family members (EGFR [ErbB1], HER2 [ErbB2], ErbB3 and ErbB4). Based on the results of two large Phase III trials (LUX-Lung 3 [LL3] and LL6), afatinib is approved in many countries for first-line treatment of patients with advanced EGFRm+ NSCLC. More recently, following results of the Phase III LL8 trial, afatinib was also approved for treatment of squamous cell carcinoma of the lung after platinum-based chemotherapy. Overexpression/amplification of HER2 has been identified in NSCLC and may have a role in acquired resistance to reversible EGFR tyrosine kinase inhibitors. Afatinib has demonstrated preclinical activity in HER2m+ lung cancer models and clinical activity in HER2m+ NSCLC patients (de Greve et al. Lung Cancer 2012; Mazieres et al. Ann Oncol 2015). This Phase II trial investigates the efficacy and safety of afatinib in patients with advanced NSCLC harbouring HER2 mutations, previously treated with chemotherapy (NCT02597946). In this Phase II, open-label, single-arm trial, eligible patients are aged ≥18 years, with ECOG PS 0/1, histologically or cytologically confirmed stage IV NSCLC, confirmed HER2m+ tumor tissue, and measurable disease (RECIST v1.1), following failure of one or two prior chemotherapy regimens, of which one is platinum-based. Prior radiotherapy (except palliative treatment), chemotherapy or immunotherapy within 4 weeks, hormonal therapy within 2 weeks, or EGFR/HER2-targeted therapy is not allowed. In Part A of this two-part trial, patients will receive continuous oral afatinib monotherapy at the approved starting dose of 40 mg/day. The dose may be escalated to 50 mg/day after 4 weeks in patients with minimal drug-related adverse events (AEs); dose reduction by 10-mg decrements to a minimum of 20 mg/day will occur in case of drug-related grade ≥3 or selected grade 2 AEs. In Part B, patients with ECOG PS ≤2 experiencing >12 weeks of clinical benefit with afatinib monotherapy before disease progression will continue treatment with afatinib plus weekly intravenous paclitaxel 80 mg/m2. In Parts A and B, treatment will continue until disease progression or intolerable AEs. The primary endpoint is objective response in Part A. Secondary endpoints include: disease control, progression-free survival, time to progression, and duration of response in Part A; and overall survival. Safety will also be assessed. Target enrolment is 40 patients, and participating countries will be listed in the full presentation. Section not applicable. Section not applicable.

Successful Treatment of a Patient with NSCLC Carrying Uncommon Compound L861Q/G719X Epidermal Growth Factor Receptor Mutations Using Afatinib

Case Report: Favorable Efficacy of Combined Afatinib and Anlotinib Treatment in a Lung Adenocarcinoma Patient Harboring Uncommon EGFR L858M/L861R Mutations

Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations

Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report

Non-small-cell Lung Cancer with Epidermal Growth Factor Receptor L861Q-L833F Compound Mutation Benefits from Both Afatinib and Osimertinib: A Case Report.

Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I

Interim Analysis of Afatinib Monotherapy in Patients with Metastatic Nsclc Progressing after Chemotherapy and Erlotinib/Gefitinib (E/G) in A Trial of Afatinib Plus Paclitaxel Versus Investigator'S Choice Chemotherapy Following Progression on Afatinib Monotherapy

Durable Complete Response After Afatinib And Crizotinib In An Advanced Non-Small Cell Lung Cancer Patient With Egfr L861q Mutation And Acquired Met Amplification: A Case Report

Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation

Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report

Uncommon EGFR Mutations in a Cohort of Chinese NSCLC Patients and Outcomes of First-Line EGFR-TKIs and Platinum-Based Chemotherapy.

Afatinib 30 Mg in the Treatment of Common and Uncommon EGFR-mutated Advanced Lung Adenocarcinomas: a Retrospective, Single-Center, Longitudinal Study

Efficacy of befotertinib in non-small cell lung cancer harboring uncommon compound EGFR mutations G719X and S768I: a case report

P2.06-013 Afatinib in Patients with Advanced HER2 Mutation-Positive (M+) NSCLC Previously Treated with Chemotherapy: Topic: Phase II + NK

Afatinib in the Treatment of Advanced NSCLC with EGFR Mutation: an Observational Real-World Study.

Afatinib As a Potential Therapeutic Option for Patients with NSCLC with EGFR G724S

A case report of a dramatic response to Afatinib in a patient with advanced adenosquamous carcinoma lung cancer (ASC) harboring EGFR L861R

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report

EGFR (p. G719A+L747V)/EML4-ALK Co-alterations in Lung Adenocarcinoma with Leptomeningeal Metastasis Responding to Afatinib Treatment: A Case Report

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation

Case Report: Afatinib Sensitivity in Rare EGFR E746_L747delinsIP Mutated LUAD With Peritoneal Metastases